Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands

Bioorganic & Medicinal Chemistry Letters
2014.0

Abstract

The design, synthesis, and biological evaluation of a series of six HIV-1 protease inhibitors incorporating isosorbide moiety as novel P2 ligands are described. All the compounds are very potent HIV-1 protease inhibitors with IC50 values in the nanomolar or picomolar ranges (0.05-0.43 nM). Molecular docking studies revealed the formation of an extensive hydrogen-bonding network between the inhibitor and the active site. Particularly, the isosorbide-derived P2 ligand is involved in strong hydrogen bonding interactions with the backbone atoms.

Knowledge Graph

Similar Paper

Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands
Bioorganic & Medicinal Chemistry Letters 2014.0
Design and synthesis of potent HIV-1 protease inhibitors incorporating hydroxyprolinamides as novel P2 ligands
Bioorganic & Medicinal Chemistry Letters 2011.0
Design and Synthesis of Potent HIV-1 Protease Inhibitors Incorporating Hexahydrofuropyranol-Derived High Affinity P<sub>2</sub> Ligands: Structure−Activity Studies and Biological Evaluation
Journal of Medicinal Chemistry 2011.0
Design of HIV-1 Protease Inhibitors with Pyrrolidinones and Oxazolidinones as Novel P1′-Ligands To Enhance Backbone-Binding Interactions with Protease: Synthesis, Biological Evaluation, and Protein−Ligand X-ray Studies
Journal of Medicinal Chemistry 2009.0
Highly Potent HIV-1 Protease Inhibitors with Novel Tricyclic P2 Ligands: Design, Synthesis, and Protein–Ligand X-ray Studies
Journal of Medicinal Chemistry 2013.0
Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands
European Journal of Medicinal Chemistry 2018.0
Flexible Cyclic Ethers/Polyethers as Novel P2-Ligands for HIV-1 Protease Inhibitors: Design, Synthesis, Biological Evaluation, and Protein−Ligand X-ray Studies
Journal of Medicinal Chemistry 2008.0
Design of HIV-1 Protease Inhibitors with C3-Substituted Hexahydrocyclopentafuranyl Urethanes as P2-Ligands: Synthesis, Biological Evaluation, and Protein–Ligand X-ray Crystal Structure
Journal of Medicinal Chemistry 2011.0
Structure-Based Design of Novel HIV-1 Protease Inhibitors To Combat Drug Resistance
Journal of Medicinal Chemistry 2006.0
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl design
Journal of Medicinal Chemistry 1992.0